Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HK1 | P19367 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5911773 | 0.91 | PDE10A (0.58) | PDE10APDGFRBEGFRCSF1RMAPT | |
| SCHEMBL5244659 | 0.89 | ADRA1D (0.55) | PDE10APDGFRBMAPTKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5292124 | 0.88 | ADRA1D (0.54) | PDE10APDGFRBMAPTKMT2AALDH1A1 | |
| SCHEMBL5247596 | 0.87 | PDE10A (0.46) | PDE10APDGFRBACHEMAPTKMT2A | |
| SCHEMBL5246573 | 0.87 | PDE10A (0.46) | PDE10APDGFRBACHEMAPTKMT2A | |
| SCHEMBL5287072 | 0.87 | PDGFRB (0.47) | PDE10APDGFRBMAPTKMT2AALDH1A1 | |
| SCHEMBL5301608 | 0.87 | PDGFRB (0.47) | PDE10APDGFRBMAPTKMT2AADRA1D | |
| SCHEMBL5293604 | 0.87 | PDE10A (0.48) | PDE10APDGFRBEGFRACHEMAPT | |
| SCHEMBL5243560 | 0.86 | RAB9A (0.51) | PDE10APDGFRBACHEMAPTKMT2A | |
| SCHEMBL8266253 | 0.86 | ADRA1D (0.48) | PDE10APDGFRBEGFRMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802585-A1 | 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | claimed |
| EP-1802585-A1 | 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-20 | — | — | US | disclosed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | PDE5A, PDE3A, PDE2A | PDE10A 8/4885PDGFRB 992/4885EGFR 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.